Published in Gene Therapy Weekly, October 20th, 2005
More effective and comprehensive testing of target groups could reveal more about the as yet little-studied sexually transmitted bacterial disease mycoplasma, just is as already done to demonstrate other sexually transmitted illnesses such as chlamydia and gonorrhea. The DNA test products are developed by the Norwegian company Genpoint AS. Genpoint's methods identify and analyze bacterial diseases by mean of DNA...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2005-10-20)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.